Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of $11.85 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
